Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cysteine-rich secretory protein LCCL domain-containing 2 (CRISPLD2) is a secreted protein belonging to the CRISP family and the broader mammalian CAP superfamily. It contains an LCCL domain and has alternative splice variants resulting in multiple isoforms. CRISPLD2 has been reported to promote extracellular matrix assembly and may have functions in protease inhibition, morphogenesis, and possibly other paracrine/endocrine roles. No drugs are currently known to target CRISPLD2, nor is it prominently associated with major disease pathology outside of a genetic association with orofacial clefting. Synonyms include CRISP11, LCRISP2, and LGL1, among others.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cysteine-rich secretory protein LCCL domain-containing 2 (CRISPLD2).